What happened, in summary

Stephanie Dobson was 34 and recently postpartum when persistent gastrointestinal symptoms led to a colonoscopy in September 2023 and a diagnosis of rectal cancer. Molecular testing showed high-level microsatellite instability, or MSI-high disease, which made immunotherapy an important treatment option. Further genetic evaluation confirmed Lynch syndrome, a hereditary cancer condition that also has implications for Stephanie's children and other relatives. She began immunotherapy in September at Dana-Farber's Young-Onset Colorectal Cancer Center. The treatment allowed her to avoid some of the major lifestyle changes associated with chemotherapy, radiation, and surgery, and its side effects remained manageable. Early fatigue began to improve, and the rectal tumor was shrinking. The hereditary diagnosis was emotionally difficult because of what it could mean for her family, but it also allowed relatives to consider genetic testing and earlier cancer screening. Stephanie continues treatment while focusing on her young family and on raising awareness about persistent colorectal symptoms and the importance of follow-up.